Alnylam Pharmaceuticals (NASDAQ:ALNY), with a market capitalization of $35.4 billion, has emerged as a leading player in the RNA interference (RNAi) therapeutics space, with a particular focus on ...

Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.

The patient’s RA was managed with leflunomide and etanercept for the past 5 years. Researchers from the US presented the case of a patient with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) ...

[18F]florbetaben has demonstrated its capability to identify amyloid deposits in the heart, including AL and ATTR. These findings led to its Orphan Drug Designation by both the European Commission and ...

[18F]florbetaben has demonstrated its capability to identify amyloid deposits in the heart, including AL and ATTR. These findings led to its Orphan Drug Designation by both the European Commission ...

These included heart failure, cardiac arrhythmias, cardiomegaly, carpal tunnel syndrome, chronic kidney disease, and peripheral neuropathy. Recognizing these associated features ... Screening for ...

People with transthyretin cardiac amyloidosis (ATTR-CA) on top of aortic stenosis ... and autonomic and peripheral neuropathy. "Recognizing these associated features could help clinicians identify ...

Next up is the CARDIO-TTRansform trial on transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Could you explain the significance of this trial and its potential to reshape the treatment ...

In the longest study of an RNAi therapeutic for any disease, patisiran treatment demonstrated modest improvements in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy ...

Additionally, Orphan Drug Designations have been granted to 124 I-evuzamitide as a diagnostic for the management of ATTR and AL amyloidosis by both the US FDA and the European Commission.